Several studies on various cancers such as glioblastoma, melanoma, and head and neck squamous cell carcinoma (HNSCC) have reported on the role of serum-derived exosomal PD-L1 levels as a potential predictive biomarker for ICIs therapies (12, 47, 48). This evidence concerns the gene CD274 and glioblastoma.